Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Cadrenal Therapeutics Q1 EPS $(2.09) Misses $(1.25) Estimate

Author: Benzinga Newsdesk | May 08, 2025 07:13am
Cadrenal Therapeutics (NASDAQ:CVKD) reported quarterly losses of $(2.09) per share which missed the analyst consensus estimate of $(1.25) by 67.2 percent. This is a 39.33 percent decrease over losses of $(1.50) per share from the same period last year.

Posted In: CVKD

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist